REG - BSF Enterprise PLC - Publication of New Research

BSF EnterpriseAnnouncement

01/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230601:nRSA2225Ba&default-theme=true

RNS Number : 2225B  BSF Enterprise PLC  01 June 2023

1 June 2023

 

BSF Enterprise PLC

("BSF" or the "Company")

 

Publication of New Research

BSF (LSE: BSFA; OTCQB: BSFAF), the Main Market listed biotech company and the
owner of pioneering UK-based clinical and cellular agriculture company 3D
Bio-Tissues, is pleased to inform shareholders that a new research note on the
Company has recently been published by Shard Capital Partners LLP.

The note can be found on the Company's website, www.bsfenterprise.com
(http://www.bsfenterprise.com) , or via the Shard Portal
(https://shardcapital.com/capital-markets/corporate-broking/research-portal/#/portal/shard-capital/research/b1acaafa-e70d-41c0-90dd-5827fc37dfc0)
.

 

-Ends-

 

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com/)  or contact:

 BSF Enterprise PLC                         Via SEC Newgate below
 Che Connon - CEO & Executive Director

 Geoff Baker - Executive Director

 Shard Capital (Broker)
 Damon Heath                                0203 971 7000

 Isabella Pierre                            0207 1869 927

 SEC Newgate (Financial Communications)
 Bob Huxford                                020 3757 6882

 Elisabeth Cowell                           BSF@secnewgate.co.uk

 George Esmond

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.

 

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas to help restore
vision to millions of people. Building on this success, it has produced the
UK's first high quality lab-grown meat from its laboratory using its
technology.

 

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
acquiring complementary businesses. It aims to acquire a suite of technologies
that underpins the development of tissue templating for corneas, meat and
leather, and license out the IP to manufacturers, wholesalers and distributors
to help manufacture the products at scale.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DOCEFLFXXELFBBV